RecruitingPhase 4NCT07308717
Gabapentin And Breast Surgery Decision Architecture Randomization Trial (GABS-DART) Protocol
Sponsor
Memorial Sloan Kettering Cancer Center
Enrollment
1,896 participants
Start Date
Dec 16, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
This study aims to assess whether gabapentin should be a standard component of peri-operative pain control in mastectomy patients at Memorial Sloan Kettering Cancer Center.
Eligibility
Min Age: 18 YearsMax Age: 65 Years
Plain Language Summary
Simplified for easier understanding
This trial studies different approaches to managing pain medication (gabapentin) and decision-making after mastectomy surgery to find what works best for patients.
**You may be eligible if...**
- You are 18–65 years old
- You are having an ambulatory extended recovery mastectomy (bilateral or unilateral) at the Josie Robertson Surgical Center
**You may NOT be eligible if...**
- There are no exclusion criteria for this trial
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERModification to Pre-operative Order Set
Modification to the pre-operative order set to remove gabapentin
Locations(7)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07308717
Related Trials
Genomic Services Research Program
NCT025959571 location
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
NCT052833304 locations
Sodium-glucose Transporter Type 2 Inhibition in Anthracycline-related Cardiotoxicity
NCT070707652 locations
Social and Environmental Determinants of Breast Cancer Survivorship: the Black Breast Cancer Survivor's Intervention (BBCSI)
NCT068852031 location
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
NCT06103864316 locations